MedTrace Logo

A Study of HDM2012 in Patients With Advanced Solid Tumor

NCT07100249 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2025-08-08

No results posted yet for this study

Summary

This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2012 in patients with advanced solid tumors.

Conditions

Interventions

DRUG

HDM2012

HDM2012 will be administered via IV infusion.

Sponsors & Collaborators

  • Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-06
Primary Completion
2027-10-31
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07100249 on ClinicalTrials.gov